Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin‐3, and NT‐ProBNP Before Cardiac Surgery
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
BackgroundCurrent preoperative models use clinical risk factors alone in estimating risk of in‐hospital mortality following cardiac surgery. However, novel biomarkers now exist to potentially improve preoperative prediction models. An assessment of Galectin‐3, N‐terminal pro b‐type natriuretic peptide (NT‐ProBNP), and solubleST2 to improve the predictive ability of an existing prediction model of in‐hospital mortality may improve our capacity to risk‐stratify patients before surgery.Methods and ResultsWe measured preoperative biomarkers in the NNECDSG (Northern New England Cardiovascular Disease Study Group), a prospective cohort of 1554 patients undergoing coronary artery bypass graft surgery. Exposures of interest were preoperative levels of galectin‐3,NT‐ProBNP, andST2. In‐hospital mortality and adverse events occurring after coronary artery bypass graft were the outcomes. After adjustment,NT‐ProBNPandST2 showed a statistically significant association with both their median and third tercile categories withNT‐ProBNPodds ratios of 2.89 (95% confidence interval [CI]: 1.04–8.05) and 5.43 (95%CI: 1.21–24.44) andST2 odds ratios of 3.96 (95%CI: 1.60–9.82) and 3.21 (95%CI: 1.17–8.80), respectively. The model receiver operating characteristic score of the base prediction model (0.80 [95%CI: 0.72–0.89]) varied significantly from the new multi‐marker model (0.85 [95%CI: 0.79–0.91]). Compared with the Northern New England (NNE) model alone, the full prediction model with biomarkersNT‐proBNPandST2 shows significant improvement in model classification of in‐hospital mortality.ConclusionsThis study demonstrates a significant improvement of preoperative prediction of in‐hospital mortality in patients undergoing coronary artery bypass graft and suggests that biomarkers can be used to identify patients at higher risk.
